John Reddington

PhD/DVM, Life Science Executive

Co-founder & Senior Partner XOventure

Currently Chief Operating Officer at Cambridge Biomedical, MA (USA), John has for the last 23 years started and/or managed several private and public biotech companies. Most recently he served as President and CEO of Sirtex Medical, Inc., the US division of the Australian publicly traded company Sirtex Medical Group Ltd. (ASX: SIR), where he reorganized and revitalized the US division which accounts for approximately 80% of the corporation’s Aus$66 million in revenue.  During John’s last year with Sirtex the divisional sales increased by 29% while expenses were trimmed by 6%, which contributed significantly to the 1,406% increase in net profit (after taxes) that the Company enjoyed. 

Prior to joining Sirtex, John was COO and SVP of R&D for the publicly traded company Valentis Inc., where he played a key role in transitioning Valentis’ clinical focus from gene therapy to poloxamer-based therapeutics to treat cardiovascular disease.  During his tenure John helped secure $30 million in new equity financing, as well as negotiated licensing and supply agreements up to $500 million. In addition, he was responsible for selling off all non-critical assets to facilitate a reverse merger, and spun out the manufacturing division as an independent business unit.  

Previously, John founded DiagXotics Inc. and led it to become the world leader in disease diagnosis for the $52-billion global aquaculture market.  Earlier in his career, John directed the build-out and operation of an office and cancer cell therapy laboratory for Greenwich Biotherapeutics Inc. a joint venture between Biotherapeutics Inc., Yale University and Greenwich Hospital.  John received his B.A. from Rice University, his M.A. from the University of Texas, Arlington and his DVM and PhD from Washington State University.